Total Clarity Wealth Management Inc. Has $336,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

Total Clarity Wealth Management Inc. trimmed its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 59.8% during the second quarter, Holdings Channel reports. The firm owned 6,340 shares of the biotechnology company’s stock after selling 9,441 shares during the quarter. Total Clarity Wealth Management Inc.’s holdings in Viking Therapeutics were worth $336,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Thoroughbred Financial Services LLC increased its holdings in Viking Therapeutics by 48.3% in the second quarter. Thoroughbred Financial Services LLC now owns 19,198 shares of the biotechnology company’s stock worth $1,017,000 after purchasing an additional 6,251 shares in the last quarter. Stoneridge Investment Partners LLC acquired a new stake in shares of Viking Therapeutics during the 2nd quarter worth approximately $225,000. DekaBank Deutsche Girozentrale increased its stake in shares of Viking Therapeutics by 237.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 57,330 shares of the biotechnology company’s stock valued at $3,004,000 after acquiring an additional 40,330 shares in the last quarter. Meeder Asset Management Inc. lifted its position in shares of Viking Therapeutics by 140.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 802 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 469 shares during the period. Finally, Oppenheimer & Co. Inc. boosted its stake in Viking Therapeutics by 45.7% during the second quarter. Oppenheimer & Co. Inc. now owns 71,313 shares of the biotechnology company’s stock worth $3,780,000 after acquiring an additional 22,369 shares in the last quarter. Institutional investors own 76.03% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on VKTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Viking Therapeutics in a research note on Thursday, July 25th. JPMorgan Chase & Co. started coverage on Viking Therapeutics in a research note on Wednesday, September 11th. They set an “overweight” rating and a $80.00 price target on the stock. Maxim Group reissued a “buy” rating and issued a $120.00 price objective on shares of Viking Therapeutics in a research note on Tuesday, June 4th. Raymond James boosted their price objective on Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a report on Thursday, July 25th. Finally, StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $108.60.

Viking Therapeutics Trading Up 0.6 %

Shares of NASDAQ:VKTX opened at $67.10 on Tuesday. The stock has a market cap of $7.43 billion, a PE ratio of -72.15 and a beta of 1.00. The stock’s fifty day simple moving average is $58.32 and its two-hundred day simple moving average is $63.65. Viking Therapeutics, Inc. has a 1-year low of $8.28 and a 1-year high of $99.41.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.06. During the same quarter in the previous year, the firm earned ($0.19) EPS. On average, sell-side analysts forecast that Viking Therapeutics, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Transactions at Viking Therapeutics

In related news, COO Marianna Mancini sold 18,026 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $57.13, for a total transaction of $1,029,825.38. Following the completion of the sale, the chief operating officer now directly owns 362,149 shares of the company’s stock, valued at $20,689,572.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Brian Lian sold 115,859 shares of the company’s stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $57.58, for a total transaction of $6,671,161.22. Following the transaction, the chief executive officer now owns 2,354,927 shares of the company’s stock, valued at approximately $135,596,696.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Marianna Mancini sold 18,026 shares of Viking Therapeutics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.13, for a total value of $1,029,825.38. Following the completion of the sale, the chief operating officer now directly owns 362,149 shares of the company’s stock, valued at approximately $20,689,572.37. The disclosure for this sale can be found here. Insiders have sold 290,241 shares of company stock worth $17,786,475 in the last 90 days. Insiders own 4.70% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.